John Coletta, MD
Interventional Cardiology · Westlake, OHNPI 1609997071
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $110,510 of the $127,940 with a category attached, or 86.4%. Johnson & Johnson accounts for 94.1% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $59,972 and has fallen 94.7% since, to $3,200 in 2025. Among interventional cardiology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 284 payments — averaging $450.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$120K
- Abbott$4K
- Medtronic$719
- Novartis$572
- Shockwave Medical, Inc$481
- AstraZeneca$280
- plus $1K from 22 others
What the payments were for
- Consulting fees$3,0002%
- Speaking & faculty fees$110,51086%
- Travel & lodging$6,0905%
- Food & beverage$8,3287%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 111 | $120,360 |
| Abbott | 33 | $4,135 |
| Medtronic(2 entities) | 21 | $719 |
| Novartis | 26 | $572 |
| Shockwave Medical, Inc | 16 | $481 |
| AstraZeneca | 13 | $280 |
| Vifor Pharma, Inc. | 3 | $173 |
| Boston Scientific | 5 | $166 |
| Boehringer Ingelheim | 8 | $156 |
| Esperion Therapeutics, Inc. | 8 | $153 |
| E.r. Squibb & Sons, L.L.C. | 7 | $116 |
| Amgen | 7 | $114 |
| GE HealthCare | 1 | $79 |
| Amarin Pharma, Inc. | 5 | $74 |
| Gilead | 3 | $57 |
| Pfizer | 3 | $47 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $42 |
| Abiomed | 2 | $40 |
| Irhythm Technologies, Inc. | 1 | $28 |
| Bolton Medical Inc | 1 | $24 |
| Chiesi USA, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| EKOS Corporation | 1 | $15 |
| Terumo Medical Corporation | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Cardinal Health 200 LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$118,024
- OPTIS$2,967
- DRAGONFLY OPSTAR$170
- Diamondback Coronary$148
- ONYX FRONTIER$133
- Veltassa$121
How this compares
$127,940 in reported general payments places this provider in the 90th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 504 | $549,112 |
| EliquisApixaban | 393 | $439,885 |
| EntrestoSacubitril/Valsartan | 154 | $204,393 |
| Repatha SureclickEvolocumab | 56 | $52,456 |
| Praluent PenAlirocumab | 55 | $40,757 |
| JardianceEmpagliflozin | 42 | $40,717 |
| FarxigaDapagliflozin Propanediol | 37 | $37,448 |
| BrilintaTicagrelor | 22 | $14,094 |
| VascepaIcosapent Ethyl | 17 | $12,950 |
| Metoprolol Succinate | 780 | $9,399 |
| Atorvastatin Calcium | 1,110 | $8,881 |
| Ranolazine ErRanolazine | 56 | $6,030 |
| Ezetimibe | 222 | $5,323 |
| LivaloPitavastatin Calcium | 15 | $4,980 |
| Rosuvastatin Calcium | 328 | $4,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $120,360 | $549,112504 claims |
| PfizerEliquis | $47 | $439,885393 claims |
| NovartisEntresto | $572 | $204,393154 claims |
| AstraZenecaFarxiga, Brilinta | $280 | $51,54259 claims |
| Boehringer IngelheimJardiance | $156 | $40,71742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Westlake
- Gary AnselColumbus$3.3M
- John CheathamColumbus$1.4M
- Carlos Sanchez SotoColumbus$1.1M
- Steven YakubovColumbus$907K
- Timothy HenryCincinnati$605K
- Mitchell SilverColumbus$562K
- John PhillipsColumbus$410K
- John CorlCincinnati$390K
- Santiago GarciaCincinnati$360K
- Atish MathurMansfield$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.